Sangamo Therapeutics, Inc (SGMOQ)
SGMOQ is quoted over the counter, not listed on an exchange. Sangamo Therapeutics, Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | SGMOQ, quoted over the counter |
| SEC CIK | 0001001233 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | Richmond, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These risks and uncertainties include, without limitation: There is substantial doubt about our ability to continue to operate as a going concern." | 10-Q 2026-05-14 |
| Cash and burn | $27.6M cash; operating cash flow -$22.6M a quarter. | Report 2026-03-31 |
| Shares outstanding | 414,288,847 (2026-05-11); 233,166,972 a year earlier; 171,825,530 three years earlier. | Cover page 2026-05-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-02-04 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-20 |
| Delisting | 25-NSE filed | 25-NSE 2026-10-07 |
| Auditor | Ernst & Young LLP, San Mateo, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-07-01 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-08-17 |
| Insider trades, 12 months | Bought $0, sold $107K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2026 2026-03-31 | $1.4M | -$31.0M | -$19.3M | $27.6M | No debt tags | $34.6M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $14.2M | -$37.4M | -$24.4M | $20.9M | No debt tags | $39.6M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $581K | -$34.9M | -$28.5M | $29.6M | No debt tags | $32.9M | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | $18.3M | -$20.0M | -$18.2M | $38.3M | No debt tags | $81.7M | 10-Q 2025-08-07 |
| Q1 2025 2025-03-31 | $6.4M | -$30.6M | -$26.1M | $25.2M | No debt tags | $63.8M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $7.6M | -$23.4M | -$3.4M | $41.9M | No debt tags | $57.8M | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | $49.4M | $10.7M | $11.8M | $39.2M | No debt tags | $52.3M | 10-Q 2025-11-06 |
| Q2 2024 2024-06-30 | $356K | -$36.1M | -$26.9M | $27.8M | No debt tags | $12.3M | 10-Q 2025-08-07 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-04 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-05-14 |
| Latest current report | 8-K | 2026-10-27 |
| Latest proxy | DEF 14A | 2025-04-30 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier